Inspire Medical Q1 2026: Revenue Uplift from Medicare Reimbursement Partially Offsets Persistent GLP-1 Headwinds

What happened

Inspire Medical Systems reported Q1 2026 revenue of approximately $225 million, slightly above consensus, as the 50% Medicare facility-fee boost for its sleep apnea implant began to take effect. Gross margin remained resilient at 85%, but procedure volume growth decelerated to mid-single digits, reflecting ongoing patient preference for GLP-1 therapies and cautious provider adoption. The company updated its 2026 revenue guidance to $1.05-$1.07 billion, implying ~12% growth at the midpoint, while raising EPS guidance to $1.25-$1.35 due to improved operating leverage. However, management acknowledged that GLP-1 competition is structurally capping volume expansion, and the DOJ investigation over marketing practices remains unresolved. The results suggest that the reimbursement tailwind is material but insufficient to fully restore the prior growth trajectory.

Implication

Investors should view this quarter as confirmation that the 2026 Medicare reimbursement uplift is real and accretive to earnings, but the fundamental challenge from GLP-1 therapies remains intact. The low volume growth despite better per-procedure economics argues that Inspire's total addressable market is being structurally compressed, limiting revenue growth to the low teens at best. While the balance sheet and cash flow remain strong, the elevated P/E multiple (~55x trailing) still leaves little room for error. For risk-tolerant investors, the stock may offer a modest upside if volume re-accelerates, but the DOJ investigation and potential for further GLP-1 adoption make it a hold rather than a buy. The thesis hinges on whether the reimbursement boost can sustainably lift volumes over the next 12-18 months, which remains uncertain.

Thesis delta

The thesis shifts from 'stabilization after a reset' to 'modest recovery but capped by competition.' The Medicare reimbursement uplift is proving effective in protecting margins and boosting EPS, but volume growth is clearly constrained by GLP-1 alternatives. This suggests that Inspire is becoming a high-margin, low-growth franchise, which may justify a lower multiple than previously assumed. The risk-reward remains balanced, but the upside beyond $120-130 appears limited without a catalyst to reignite volume growth.